ACI-7104.056

AC Immune is testing ACI-7104.056, an active vaccine that trains the patient's own immune system to produce antibodies against pathological alpha-synuclein, the protein that misfolds and forms clumps called Lewy bodies inside Parkinson's neurons [1]. The Phase 2 trial NCT06015841 enrolled 150 patients with early-stage Parkinson's across at least two dose cohorts and is no longer recruiting, with the primary readout focused on safety and immunogenicity rather than clinical efficacy [1]. If the vaccine works, it could slow disease progression by clearing the toxic protein driving neuron death, which would be fundamentally different from current drugs like levodopa that only mask motor symptoms while the underlying neurons keep dying. The bet is high-risk: every passive anti-synuclein antibody tested in Parkinson's so far has missed or barely cleared its primary endpoint [2], and active vaccines targeting misfolded brain proteins carry the legacy of AN1792, the first-generation anti-amyloid vaccine for Alzheimer's that triggered meningoencephalitis in roughly 6% of patients [3]. AC Immune is a small-cap Swiss biotech with no approved drug; the Parkinson's program is one of two main value drivers alongside its Alzheimer's vaccine partnered with Takeda [4]. Watchable, but the synuclein hypothesis itself is still being adjudicated by competitor readouts that will arrive first.

ACI-7104.056 is a novel investigational vaccine, never approved anywhere. It is the optimized successor to PD01A, the active immunotherapy AC Immune acquired when it bought AFFiRiS's Parkinson's program in 2021 [5]. PD01A had shown some immunogenicity in earlier Phase 1 studies but was not advanced in that form, which is informative: the predecessor data validates that the platform can raise antibodies, but it also tells you the earlier construct was not good enough to push forward as-is. Phase 2 trial NCT06015841 began in late 2023 and is currently Active, Not Recruiting as of 2026, meaning the 150-patient cohort is fully dosed and in follow-up [1]. AC Immune publicly disclosed dose-dependent anti-alpha-synuclein antibody responses from an interim look at this program, but the full Phase 2 dataset including biomarker and clinical endpoints is still pending [4]. With dosing complete and 12-month follow-up the typical readout window for a vaccine immunogenicity-and-biomarker study, full results are most plausibly a 2027 catalyst, with interim biomarker updates possible in 2026. No FDA Breakthrough Therapy, Fast Track, RMAT, or Orphan designations are listed for this asset. Parkinson's disease is too prevalent (~1 million US patients) for Orphan Drug Designation, so the absence of FDA priority pathways here is about the regulatory submission package and the strength of early clinical data, not the agency's view of the mechanism. Regulatory submission, if Phase 2 succeeds, is years away, likely no earlier than 2030. AC Immune will almost certainly need a Big Pharma partner to fund Phase 3 in Parkinson's, which typically requires 1,500-plus patients followed over multiple years to detect a disease-modifying signal. On the balance sheet: AC Immune reported CHF 74.8 million in cash and short-term financial assets as of 31 March 2026, with guided runway into Q4 2027, helped by a CHF 10M Lilly upfront expected in Q2 2026 [9]. That is a real runway for an interim biomarker readout and a partnership conversation, but not enough to self-fund Phase 3.

Alpha-synuclein is a small protein normally found at the tips of neurons, where it helps the cell package and release neurotransmitters like dopamine. In Parkinson's, the protein misfolds, sticks to other misfolded copies, and forms toxic clumps called Lewy bodies inside neurons. These aggregates appear to spread cell-to-cell, killing dopamine-producing neurons in the substantia nigra and causing the tremor, slowness, and rigidity that define Parkinson's. ACI-7104.056 is an active immunotherapy, meaning a therapeutic vaccine. Instead of infusing manufactured antibodies (the passive immunotherapy strategy used by prasinezumab and cinpanemab), the vaccine teaches the patient's own immune system to make antibodies against the pathological form of alpha-synuclein, while ideally leaving the normal monomer alone. The advantages of a vaccine over infused antibodies are real: cheaper to manufacture, monthly or quarterly dosing instead of IV infusions, and potentially better long-term coverage. The disadvantages are also real: less control over the antibody response in any individual patient, and a slow ramp-up of titers that may not match what infused mAbs achieve quickly. The genetic case for alpha-synuclein as a Parkinson's target is strong. Families with SNCA gene duplications, triplications, or specific point mutations get Parkinson's in a dose-dependent way, with triplication carriers developing severe disease in their 30s and 40s [6]. The therapeutic case is weaker. Roche/Prothena's prasinezumab missed its primary endpoint in PASADENA Phase 2, and Biogen's cinpanemab failed outright in SPARK [2, 7]. Whether a vaccine generates antibodies of the right specificity and titer to outperform what direct antibody infusion has not managed is the open question.

NCT06015841 is a Phase 2, double-blind, placebo-controlled study enrolling 150 patients with early Parkinson's disease, sponsored by AC Immune [1]. The trial is structured around at least two ACI-7104.056 dose levels plus placebo, run in parallel to identify the dose that produces the best balance of antibody titer, target engagement, and tolerability. The node ID flags this as the Dose A (lower dose) analysis specifically; the higher dose arm is being read out alongside it. For an active vaccine, dose is not a minor variable - immunogenicity, titer durability, and the risk of T-cell-driven autoimmunity all move with dose, and AC Immune's eventual Phase 3 design depends on which arm wins this comparison. The listed primary endpoint is adverse events graded by severity and causal relationship, a safety and immunogenicity readout rather than a clinical efficacy readout. That is the right call for a vaccine at this stage: the first question is whether the immune system mounts a sustained, specific antibody response against pathological alpha-synuclein without triggering autoimmune problems. Efficacy signals will come from secondary endpoints, including MDS-UPDRS motor scores (the Movement Disorder Society Unified Parkinson's Disease Rating Scale, a clinician-scored composite of motor and non-motor symptoms - the standard primary endpoint for disease-modifying Parkinson's trials), dopamine transporter imaging (DaT-SPECT, which measures the health of dopamine neurons in the striatum), and CSF or serum biomarkers of total and pathological alpha-synuclein. The 150-patient size is reasonable for a Phase 2 immunogenicity and biomarker study but is well underpowered to call a clinical efficacy win, particularly when split across two dose arms plus placebo. Any apparent benefit on motor scores will be hypothesis-generating only and will need confirmation in a much larger Phase 3. Placebo control with sham injections is appropriate and standard for vaccine trials. Status is Active, Not Recruiting as of 2026, so enrollment risk is behind the program. The bigger uncertainty is what AC Immune shows on target engagement biomarkers. Without a clean signal that the antibodies generated by the vaccine are actually reducing pathological synuclein in the brain or CSF, this program has nowhere credible to go in Phase 3.

Our model puts the odds of this drug eventually being approved at 4%. It starts from the historical approval rate for Phase 2 drugs in this area-about 24%-then adjusts based on ten facts about the trial and sponsor. The estimate falls well below that baseline mainly because of heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The remaining factors are near average for this stage and don't shift the number much either way.

Efficacy risk is the dominant concern, by a wide margin. The synuclein hypothesis has not yet produced a clinical winner. Prasinezumab missed its primary endpoint in PASADENA Phase 2, with only post-hoc subgroup signals to feed a follow-on Phase 2b [2]. Cinpanemab failed cleanly in SPARK with no efficacy signal across any subgroup [7]. Takeda's TAK-341 (originally MEDI1341, AstraZeneca-partnered) lowered CSF free alpha-synuclein by >50% in Phase 1 but then failed its Phase 2 in multiple system atrophy in 2025, and Takeda dropped the program - strong target engagement, no clinical benefit [10]. The pattern across passive antibodies is consistent: you can hit the target in fluid, you cannot move the disease. A vaccine has additional hurdles layered on top: the antibodies generated must be specific to the pathological aggregated form but not the normal monomer, must reach the brain in adequate concentration, and must be sustained over years of dosing. Safety risk is real and class-specific. The first-generation active vaccine for Alzheimer's, AN1792 against beta-amyloid, was halted after roughly 6% of patients developed meningoencephalitis driven by T-cell autoreactivity [3]. AC Immune's design strategy targets B-cell epitopes without strong T-cell activation, but a multi-year vaccine study with chronic dosing is the only place to see slow-burn autoimmune signals emerge. Execution risk is moderate. AC Immune held CHF 74.8M in cash and short-term assets as of Q1 2026 with guided runway into Q4 2027 [9], which covers the Phase 2 readout and partnership negotiation window, but not Phase 3 on its own. The program will need a Big Pharma partner to fund Phase 3, and competing for that partnership against the larger and more advanced Roche/Prothena passive antibody is a hard pitch. Commercial risk is the final hurdle: even if the vaccine modestly slows progression, payers will demand a clean biomarker tied to long-term clinical outcome, and pricing a chronic neurology vaccine against generic levodopa is a market that has not been built before.

Worth watching, low priority until the next data drop. AC Immune's value depends more on its Alzheimer's vaccine ACI-24.060 - partnered with Takeda in a 2024 deal that gave AC Immune a $100M upfront with up to ~$2.1B in milestones plus tiered royalties [4] - than on the Parkinson's asset. Cash and short-term assets stood at CHF 74.8M as of 31 March 2026 with runway guided into Q4 2027 [9], so the company can survive to the Phase 2 readout but not much beyond without a partnership win or a follow-on raise. The specific data point to watch: the next biomarker analysis from NCT06015841, expected over the next 12-18 months, which should combine immunogenicity (antibody titers over time across the two dose cohorts) with target engagement signals (CSF or imaging alpha-synuclein readouts). Full Phase 2 results are most plausibly a 2027 catalyst. If antibody titers are high and sustained AND there is a directional drop in pathological synuclein, this becomes a real signal. Without that combination, it is one more anti-synuclein program in a crowded graveyard. Check back when the interim biomarker data drops, and re-rate immediately on any prasinezumab PADOVA Phase 2b readout from Roche/Prothena, which is the cleaner test of the synuclein hypothesis as a whole and will arrive first. If prasinezumab fails again in PADOVA, the entire active-immunotherapy program here gets devalued by association, regardless of what AC Immune's antibody titers show. Also worth tracking: Vaxxinity's UB-312, another active anti-synuclein vaccine in early clinical development - a direct mechanistic competitor with similar timeline. The fight is on a target where nobody has yet won, and the most recent passive-antibody data (TAK-341 in MSA) made that even clearer.